| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | LOXO ONCOLOGY INC COM | 3,796,362 | 103,793,000 | 20.78% | ||
| 2 | ZELTIQ AESTHETICS INCORPORATED | 2,103,528 | 57,132,000 | 11.44% | ||
| 3 | AIMMUNE THERAPEUTICS INC COM | 2,990,000 | 40,544,000 | 8.12% | ||
| 4 | TRANSENTERIX INC | 8,335,819 | 35,427,000 | 7.09% | ||
| 5 | VIEWRAY INC | 7,461,923 | 32,086,000 | 6.43% | ||
| 6 | ADMA BIOLOGICS, INC. | 3,608,171 | 29,190,000 | 5.85% | ||
| 7 | T2 BIOSYSTEMS INC | 2,830,992 | 27,914,000 | 5.59% | ||
| 8 | Esperion Therapeutics Inc | 1,637,125 | 27,684,000 | 5.54% | ||
| 9 | CEMPRA INC | 1,193,060 | 20,902,000 | 4.19% | ||
| 10 | DERMIRA INC | 970,823 | 20,077,000 | 4.02% | ||
| 11 | CATALENT INC | 715,673 | 19,087,000 | 3.82% | ||
| 12 | Agile Therapeutics, Inc. | 2,983,797 | 18,529,000 | 3.71% | ||
| 13 | VERSARTIS INC COM | 2,279,568 | 18,282,000 | 3.66% | ||
| 14 | CIDARA THERAPEUTICS INC | 1,019,455 | 12,947,000 | 2.59% | ||
| 15 | CYNAPSUS THERAPEUTICS INC | 1,021,381 | 12,154,000 | 2.43% | ||
| 16 | PARATEK PHARMACEUTICALS INC | 682,680 | 10,356,000 | 2.07% | ||
| 17 | Intersect ENT Inc | 350,000 | 6,650,000 | 1.33% | ||
| 18 | CHIMERIX INC | 472,943 | 2,417,000 | 0.48% | ||
| 19 | PERNIX THERAPEUTICS HLDGS IN | 2,010,000 | 2,111,000 | 0.42% | ||
| 20 | LOMBARD MEDICAL INC | 886,363 | 931,000 | 0.19% | ||
| 21 | PERNIX THERAPEUTICS HLDGS IN | 2,500,000 | 825,000 | 0.17% | PRN | |
| 22 | ROKA BIOSCIENCE INC | 512,920 | 354,000 | 0.07% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000950142-16-003723, filed 2016.05.13).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
